Date: 2017-09-26
Type of information: Nomination
Compound: chief medical officer
Company: Bicycle Therapeutics (UK - USA)
Therapeutic area: Cancer - Oncology
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On September 26, 2017, Bicycle Therapeutics announced the appointment of Maria Koehler as chief medical officer. Dr. Koehler will lead clinical strategy and oversee operational functions for Bicycle’s clinical development team to bring BT1718 and additional Bicycles to patients for the treatment of a range of cancers with poor survival outcomes. Dr. Koehler, a trained oncologist with two decades of industry experience, joins Bicycle from Pfizer, where she was Vice President of Strategy, Innovation and Collaborations for the Oncology Business Unit. At Pfizer, Dr. Koehler was a key member of the oncology leadership team responsible for creating and coordinating innovative strategies for their oncology pipeline from early stage clinical trials through pivotal trials and product approval. Her accomplishments at Pfizer include leading development strategies for Palbociclib/IBRANCE, which was launched in 2015, and shaping the oncology portfolio. Prior to joining Pfizer, Dr. Koehler was the Group Leader for the Medicine Development Center of GlaxoSmithKline Oncology, and a Senior Medical Director for Oncology Research and Development at AstraZeneca. During her academic career, she was the Clinical Director of Bone Marrow Transplantation at University Hospital in Pittsburgh, PA, and Director of the Bone Marrow Transplant Program and Associate Professor at St.Christopher’s Hospital in Philadelphia, PA. She is a Board Certified Hematology/Oncology physician, and the author of more than 160 peer reviewed publications and book chapters. Dr. Koehler recieved her M.D. and Ph.D. from the Silesian School of Medicine in Katowice, Poland.
Financial terms:
Latest news:
Is general: Yes
